Jenburkt Pharmaceuticals Ltd (JENA)

Currency in INR
1,195.75
-77.35(-6.08%)
Closed·

JENA Financial Summary

Key Ratios

P/E Ratio17.89
Price/Book3.34
Debt / Equity2.27%
Return on Equity20.25%
Dividend Yield1.51%
EBITDA397.40M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 72.65%
Dividend Yield
1.51%
Industry Median 0.73%
Annualised payout
18.00
Paid annually
5-Years Growth
+17.32%
Growth Streak

Earnings

Latest Release
May 20, 2025
EPS / Forecast
19.34 / --
Revenue / Forecast
429.27M / --
EPS Revisions
Last 90 days

FAQ

What were Jenburkt Pharma's earnings for the latest quarter?

The Jenburkt Pharma EPS (TTM) is 72.65. Jenburkt Pharma reported sales of 410.47, net income of 85.37, and EPS of 19.34 for the latest quarter.

What was Jenburkt Pharma's net income for the latest quarter?

Jenburkt Pharma's net income for the latest quarter was 85.37.

How did Jenburkt Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 368.93 in the previous quarter to 410.47 in the latest quarter, and net income moved from 65.08 to 85.37 compared to the previous quarter.

What is Jenburkt Pharma's net profit margin on a TTM basis?

Jenburkt Pharma's trailing twelve months (TTM) net profit margin is 21.14%.

How does Jenburkt Pharma's debt to equity ratio compare to industry standards?

Jenburkt Pharma's total debt-to-equity ratio is 2.27%.

What is Jenburkt Pharma's return on investment on a TTM basis?

Jenburkt Pharma's trailing twelve months (TTM) return on investment (ROI) is 20.25%.

What were Jenburkt Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Jenburkt Pharma reported total assets of 1,961.86 million and total liabilities of 188.19 million.

How has Jenburkt Pharma's total revenue grown this year?

Jenburkt Pharma's total revenue was 368.93 in the previous quarter and 410.47 in the latest quarter.

What is Jenburkt Pharma's gross margin on a TTM basis?

Jenburkt Pharma's trailing twelve months (TTM) gross margin is 79.68%.

What was Jenburkt Pharma's revenue per share for the latest quarter?

Jenburkt Pharma's revenue per share for the latest quarter was 301.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.